EP1196413A2 - Preparation of 7-substituted benzothiophenes - Google Patents
Preparation of 7-substituted benzothiophenesInfo
- Publication number
- EP1196413A2 EP1196413A2 EP00944592A EP00944592A EP1196413A2 EP 1196413 A2 EP1196413 A2 EP 1196413A2 EP 00944592 A EP00944592 A EP 00944592A EP 00944592 A EP00944592 A EP 00944592A EP 1196413 A2 EP1196413 A2 EP 1196413A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- substituted
- group
- unsubstituted
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention provides a novel process for the preparation of 7- substituted benzothiophene derivatives useful as intermediates in the preparation of pharmaceuticals.
- the present invention provides a process for the preparation of a compound of formula I:
- R 1a , R 1b , and R 1c are each independently H, F, Cl, C C 6 alkyl, d-C ⁇ alkoxy, halo(CrC 6 )alkyl, phenyl, N0 2 , NH 2 , or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, C 1 -C- 6 alkyl, C ⁇ -C 6 alkoxy, halo(CrC- 6 )alkyl, phenyl, N0 2 , and NH 2 ; or
- R 1a and R 1b together form a C 4 -C 7 saturated or unsaturated carbocyclic ring
- R 1c is H, F, Cl, CrC 6 alkyl,C ⁇ -C 6 alkoxy, halo(C 1 -C 6 )alkyl, phenyl, N0 2 , NH 2 , or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Ci-Ce alkyl, C- ⁇ -C 6 alkoxy, halo(CrC 6 )alkyl, phenyl, N0 2 , and NH 2 ; or
- R 1b and R 1c together form a C 4 -C 7 saturated or unsaturated carbocyclic ring
- R 1a is H, F, Cl, Br, I, C C 6 alkyl, C C 6 alkoxy, halo(C C 6 )alkyl, phenyl, N0 2 , NH 2 , or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, C ⁇ -C 6 alkyl, CrC 6 alkoxy, halo(CrC 6 )alkyl, phenyl, N0 2 , and NH 2 ;
- R 2 is H, C1-C 20 alkyl, OH, C- ⁇ -C 6 alkoxy, an unsubstituted or substituted aromatic group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted (C 3 -C 8 )cycloalkyl group;
- R 3 is H, C- ⁇ -C- 20 alkyl, an unsubstituted or substituted aromatic group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted (C 3 -C 8 )cycloalkyl group; or
- R 2 and R 3 are connected by a C-2-C 4 alkylene; or a pharmaceutically acceptable salt thereof; comprising, treating a compound of formula II; formula II wherein substituents R 1a , R 1b , and R 1c are defined as above, with a suitable base, a suitable electrophile, and a compound of formula III;
- R 2 and R 3 are defined as above, and X is a suitable leaving group
- Y is OR 4 ;
- Z is OR 5 wherein R 4 and R 5 are each independently C C ⁇ 0 alkyl; or
- Y and Z together represent a carbonyl
- Y and Z are both oxygen and are connected by a C2-C4 alkylene; followed by addition of a suitable acid catalyst.
- Halo As used herein, the terms "Halo”, “Halide” or “Hal” refers to a chlorine, bromine, iodine or fluorine atom, unless otherwise specified herein.
- Me refers to a methyl group
- Et refers to an ethyl group
- Pr refers to a propyl group
- iPr refers to an isopropyl group
- Bu refers to a butyl group
- Ph refers to a phenyl group.
- CrC 4 alkyl refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms and includes, but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and the like.
- Ci-C ⁇ alkyl refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms and includes, but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, n-hexyl, and the like.
- the term “CrC ⁇ alkyl” includes within its scope “CrC 4 alkyl”.
- C C ⁇ o alkyl refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 10 carbon atoms and includes, but is not limited to methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, pentyl, isopentyl, hexyl, 2,3-dimethyl-2-butyl, heptyl, 2,2-dimethyl-3-pentyl, 2- methyl-2-hexyl, octyl, 4-methyl-3-heptyl and the like.
- C1-C10 alkyl includes within its scope "d-C- 6 alkyl” and "CrC 4 alkyl”.
- C 1 -C 2 0 alkyl refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 20 carbon atoms and includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, 3-methylpentyl, 2-ethylbutyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n- heptadecyl, n-nonadecyl, n-eicosyl and the like.
- C -C 4 alkylene refers to a straight or branched, divalent, unsaturated aliphatic chain having from two to four carbon atoms, such as — CH CH2-, -CH2CH2CH2- or — CH2CH2CH2CH2-.
- CrC 6 alkoxy refers to a straight or branched alkyl chain having from one to six carbon atoms attached to an oxygen atom. Typical d-C 6 alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and the like. The term “d-C 6 alkoxy” includes within its definition the term “C1-C4 alkoxy”.
- (C 3 -C 8 )cycloalkyl refers to nonaromatic monocyclic and polycyclic groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and bicycio[2.2.2]octane.
- (C 3 - C 8 )cycloalkyl includes within its definition the term “(C 4 -C 6 )cycloalkyl”.
- halo(CrC 6 )alkyl refers to a straight or branched alkyl chain having from one to six carbon atoms with 1 , 2 or 3 halogen atoms attached to it.
- Typical halo(C ⁇ -C 6 )alkyl groups include chloromethyl, 2- bromoethyl, 1 -chloroisopropyl, 3-fluoropropyl, 2,3-dibromobutyl, 3-chloroisobutyl, iodo-t-butyl, trifluoromethyl and the like.
- halo(d-C 6 )alkyl includes within its definition the term "halo(CrC 4 )alkyl".
- aromatic group means the same as aryl, and refers to a monovalent carbocyclic group containing one or more fused or non- fused phenyl rings and includes, for example, phenyl, 1 - or 2-naphthyl, 1 ,2- dihydronaphthyl, 1 ,2,3,4-tetrahydronaphthyl, and the like.
- heterocyclic group refers to any 3- or 4-membered ring containing a heteroatom selected from oxygen, nitrogen and sulfur; or a 5-, 6- or 7-membered ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur or a 5-membered ring containing 4 nitrogen atoms; and includes a 5-, 6- or 7-membered ring containing one, two or three nitrogen atoms; one oxygen atom; one sulfur atom; one nitrogen and one sulfur atom; one nitrogen and one oxygen atom; two oxygen atoms in non- adjacent positions; one oxygen and one sulfur atom in non-adjacent positions; two sulfur atoms in non-adjacent positions; two sulfur atoms in adjacent positions and one nitrogen atom; two adjacent nitrogen atoms and one sulfur atom; two non-adjacent nitrogen atom; two non-adjacent nitrogen atom; two non-adjacent nitrogen atom; two non-adjacent nitrogen atom; two non-adja
- the 5-membered ring has 0-2 double bonds and the 6- and 7-membered rings have 0-3 double bonds.
- the nitrogen heteroatoms can be optionally quatemized.
- the sulfur heteroatoms may optionally be oxidized.
- the terms "heterocyclic group", “heterocyclic” or “heterocycle” also include bicyclic groups in which any of the above heterocyclic rings are fused to a benzene ring or a cyciohexane ring or another heterocyclic ring (for example, indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl or benzothienyl and the like).
- Heterocyclic groups include: azetidinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, thiazolid
- substituted as used in the term “substituted aromatic", “substituted heterocyclic” or substituted (C 3 -C 8 )cycloalkyl” signifies that one or more (for example one or two) substituents may be present.
- substituents which may be present are H, F, Cl, Br, I, d-C 6 alkyl,
- This invention includes the hydrates and the pharmaceutically acceptable salts of the compounds of formula I.
- a compound of this invention can possess a sufficiently basic functional group which can react with any of a number of inorganic and organic acids, to form a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to salts of the compounds of formula I which are substantially non-toxic to living organisms.
- Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a pharmaceutically acceptable mineral or organic acid. Such salts are also known as acid addition salts.
- Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
- organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- salts examples include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1 ,4-dioate, hexyne-1 ,6-dioate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate
- any salt of this invention is usually not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole. It is further understood that such salts may exist as a hydrate.
- step A the compound of formula II is converted to the compound of structure (A) under the following conditions.
- a compound of formula II, such as thiophenol is added to about 2 equivalents of a suitable base in a suitable organic solvent at such a rate that the temperature of the stirring solution is maintained at about 0°C to about 90°C.
- the preferred temperature range is about 25°C to about 50°C.
- Examples of a suitable base include, n- butyllithium, sec-butyllithium, tert-butyllithium, potassium tert-butoxide, sodium hydride, sodium amide, potassium amide, lithium diisopropylamide, lithium cyclohexylisopropylamide, lithium dicyclohexylamide, 2,2,6,6- tetramethylpiperidin-1 -yllithium, lithium hexamethyldisilazane or potassium hexamethyldisilazane, and the like.
- the preferred suitable base is n-butyllithium.
- a suitable organic solvent examples include cyciohexane, heptane, hexanes, or other hydrocarbon mixtures, methyl tert-butyl ether, diethyl ether, tetrahydrofuran, or mixtures thereof.
- the preferred suitable organic solvents are cyciohexane, heptane, or hexanes.
- a suitable ligand such as N,N,N',N'-tetramethylethylenediamine (TMEDA) be added to help lithiation.
- TEDA N,N,N',N'-tetramethylethylenediamine
- the compound of formula II may optionally be dissolved in the suitable organic solvent prior to addition to the strong base.
- the atmosphere above the reaction mixture be inert, such as a nitrogen or argon atmosphere.
- the reaction mixture is stirred at about 20°C to about 50°C with ambient temperature being preferred, for about 18 hours to about 48 hours, with about 20 hours being preferred.
- reaction mixture is then cooled to about -10°C to about -78°C, with about -60°C being preferred and is diluted with a suitable organic solvent.
- a suitable organic solvent examples include those that will promote solubilization of the dianion and include tetrahydrofuran or methyl tert-butyl ether.
- Tetrahydrofuran is the preferred suitable organic solvent.
- One equivalent of a suitable electrophile is added dropwise to the stirring reaction mixture maintaining the temperature below about -60°C, preferably below -50°C.
- suitable electrophile refers to a compound which is an electron pair acceptor which seeks the electron rich center of an organic compound.
- Suitable electrophiles include alkylating or hydroxylating agents, silylating agents, trialkyl borates and Micheal acceptors.
- n-alkyl halides such as n-alkyl bromides and iodides, such as, for example, methyl bromide, ethyl bromide, propyl bromide, butyl bromide, pentyl bromide, hexyl bromide, heptyl bromide, octyl bromide or nonyl bromide or methyl iodide, ethyl iodide, propyl iodide, butyl iodide, pentyl iodide, hexyl iodide, heptyl iodide, octyl iodide, nonyl iodide, and the like; n-alkanals such as acetaldehyde, propionaldehyde, butyraldehyde, pentanal, hexanal, heptan
- the suitable electrophile may optionally be dissolved in the suitable organic solvent prior to addition to the reaction mixture. After addition is complete, the reaction mixture is allowed to warm to ambient temperature. Then about one equivalent of a compound of formula III
- R 2 is H, C1-C 20 alkyl, OH, C C 6 alkoxy, an unsubstituted or substituted aromatic group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted (C 3 -C 8 )cycloalkyl group;
- R 3 is H, C1-C 20 alkyl, an unsubstituted or substituted aromatic group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted (C 3 -C 8 )cycloalkyl group; or R 2 and R 3 are connected by a C 2 -C alkylene;
- X is a suitable leaving group;
- Y is OR 4 ;
- Z is OR 5 wherein R 4 and R 5 are each independently C 1 -C1 0 alkyl; or
- Y and Z together represent a carbonyl
- Y and Z are both oxygen and are connected by a C 2 -C 4 alkylene; is added to the reaction mixture.
- suitable leaving groups, X include chlorine, bromine, iodine, methanesulfonyloxy, trifluoromethanesulfonyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy, and the like. More specifically, examples of compounds of formula III include diethyl bromoacetal, dimethyl bromoacetal, diethyl chloroacetal, and the like.
- the reaction mixture is then heated slowly at about 22°C to about 100°C, preferably about 70°C to about 100°C, for about 2 hours to about 24 hours, preferably for about 4 hours to about 6 hours. During this heating period about 20% to about 80% of the reaction mixture solvent is distilled off.
- the compound of structure (A) is then isolated and optionally purified using techniques and procedures well known to one of ordinary skill in the art. For example, the reaction mixture is cooled to ambient temperature and diluted with a suitable organic solvent, such as toluene. To this mixture is added water with mixing. The layers are separated and the aqueous layer is extracted with toluene.
- step B the compound of structure (A) is cyclized using a suitable acid catalyst to provide the compound of formula (I).
- a suitable organic solvent such as toluene and is combined with a suitable acid catalyst.
- Suitable acid catalysts include aqueous HCl, methanesulfonic acid, p-toluenesulfonic acid, polymeric sulfonic acid, acidic clays, acidic zeolites, and the like.
- the reaction is heated at a temperature of about 25°C to about 110°C, preferably about 50°C to about 90°C with 50°C being most preferred, for about 1 hours to about 24 hours with about 2 hours being preferred.
- the reaction mixture is then cooled and the product is isolated and purified using techniques and procedures well known in the art, such as extraction techniques, filtration, chromatography, recrystallization techniques, and the like.
- step A the compound of structure A' is prepared in a manner analogous to the procedure described in Scheme I, step A wherein the suitable electrophile is of the formula IV formula IV
- R 6 and R 7 are each independently H or C ⁇ -C 6 alkyl; m is the integer 0, 1 or 2; n is the integer 0, 1 or 2; and Pg is a suitable nitrogen protecting group.
- a suitable nitrogen protecting group refers to those groups intended to protect the nitrogen group against undesirable reactions during synthetic procedures. Choice of the suitable nitrogen protecting group used will depend upon the conditions that will be employed in subsequent reaction steps wherein protection is required, and is well within the knowledge of one of ordinary skill in the art. Commonly used nitrogen protecting groups are disclosed in Greene, "Protective Groups In Organic Synthesis,” (John Wiley & Sons, New York (1981)).
- Suitable nitrogen protecting groups comprise acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2- bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl,
- Preferred suitable nitrogen protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, alpha- methylbenzyl (including either chiral form thereof), allyl, methoxycarbonyl, t- butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).
- step B' the compound of structure A' is cyclized to the compound of formula la in a manner analogous to the procedure described in Scheme I, step B, with a suitable acid catalyst, such as methanesulfonic acid.
- R 8 represents H or a suitable nitrogen protecting group. It is understood that under certain conditions, the suitable acid catalyst may also subsequently effect dehydration of the to provide the compound of formula lb, for example when structure A' is benzyl protected.
- Step C the compound of formula la is then dehydrated to provide the compound of formula lb.
- the compound of formula la is dissolved in a suitable organic solvent, such as isopropyl alcohol
- a suitable dehydrating agent such as aqueous HCl, and the like.
- the reaction mixture is stirred for about 0.5 hours to about 20 hours.
- the compound of formula lb is then isolated and purified using standard techniques, such as filtration and recrystallization. For example, the reaction mixture is cooled to about 0°C for at least one hour and then filtered. The solid is washed with cold isopropyl alcohol and dried under vacuum at 50°C to provide the compound of formula lb.
- step B" the compound of structure A' is cyclized and dehydrated to provide the compound of formula lb in a manner analogous to the procedure described in Scheme I, step B, with a suitable acid catalyst which produces cyclization and dehydration of the piperidine ring, in any order.
- suitable acid catalysts to effect this reaction are aqueous HCl, methanesulfonic acid, and the like.
- Aqueous HCl and methanesulfonic acid are the preferred suitable acid catalysts.
- R 8 represents H or a suitable nitrogen protecting group.
- R 8 represents a nitrogen protecting group in formula la or formula lb
- the protecting group can be readily removed under conditions well known in the art, for example, as disclosed by Greene, "Protective Groups In Organic Synthesis," (John Wiley & Sons, New York (1981)).
- Greene "Protective Groups In Organic Synthesis," (John Wiley & Sons, New York (1981)).
- Baldwin and Li J. Chem. Soc, Chem. Comm., 261 (1988).
- step A A 3 L flask containing 238 mL TMEDA
- the reaction mixture turned clear after 10 mL of the thiophenol solution was added, and remained so during the course of the addition which lasted 50 minutes.
- the solution was stirred at room temperature (22°C) and turned cloudy after 2 h. After stirring for another 20 h at ambient temperature, the off-white suspension was cooled to -5°C, mixed with 500 mL of THF (sieve dried, nitrogen purged), stirred at -5°C for 20 minutes, and then cooled to -60°C.
- N-benzyl-4-piperidone distilled, 139.86 g, 740 mmol
- the aqueous layer was extracted with toluene (300 mL x 3, and the combined organic layers were washed with water (300 mL x 4) and brine (300 mL x 2) to give a toluene solution of title compound and by-product and residual solvent.
- the wet toluene solution was dried over anhydrous MgS0 4 , vacuum filtered, and concentrated to afford 345.0 g of crude title compound as an amber oil.
- the oil was seeded with crystals from previously made title compound, and the flask was cooled in an ice bath. Recrystallization was slow so leaving the mixture standing overnight was necessary. The title compound crystallized into a solid mass.
- the crude title compound can be easily be purified by gel filtration using Silica Gel 60 by washing the filter plug first with 9:1 hexane EtOAc to remove the above by-product, and then washing it with EtOAc to obtain the title compound as an oil and recrystallize the material according to the procedure above.
- the organic phase was saved.
- the aqueous phase was extracted with a solution of 20 mL of THF and 20 mL of toluene, and then with 20 mL of THF.
- the organic phases were combined, washed with 25 mL of 25 % NaCI (aq), dried over anhydrous MgS0 4 , gravity filtered, and concentrated to afford 0.69 g of crude free base of the title compound.
- the crude free base of the title compound was purified by gel filtration
- N-benzyl-4-(benzo[b]thiophene-7-yl)-1 ,2,3,6- tetrahydropyridine decomposes approximately 10-20% at room temperature when exposed to light and air.
- N-benzyl-4-(benzo[b]thiophene-7-yl)- 1 ,2,3,6-tetrahydropyridine hydrochloride after one month at room temperature when exposed to light and air.
- Step B' A 3-neck 500 mL roundbottom flask fitted with a condenser, dropping funnel and nitrogen purge, was charged with toluene (600 mL) and methanesulfonic acid (202 mL, 300 g, 6.5 eq). The mixture was heated to 45-55oC, and 1-N-benzyl-4-hydroxy-4-(2'-(2",2"-0-diethoxy)ethylthio- phenyl)piperidine (200 g, 481.4 mmol, prepared in example 1) dissolved in toluene (1400 mL) was added over approximately 30 minutes maintaining the temperature at 45-50°C.
- the reaction mixture was stirred for about 1 to 2 hours at 45-55°C and then quenched with a mixture of 2N sodium hydroxide (1685 mL, 7 eq) and isopropyl alcohol (400 mL). The layers were separated and the organic phase was washed with water (1000 mL). Approximately 800 mL of solvent were removed under vacuum (less than 100 mm Hg) and silica G60 (160 g) was added. The mixture was then stirred for at least 30 minutes at room temperature. The mixture was then filtered and the silica G60 was rinsed with toluene (1000 mL). The filtrate was concentrated under vacuum (less than 100 mm Hg) to a final pot volume of about 400 mL. The title compound could then be isolated by complete concentration under vacuum or, alternatively, it is allowed to remain in the toluene and carried on to the dehydration step C.
- Example 4 Alternative Preparation of N-Benzyl-4-(benzorblthiophene-7-yl)-1 ,2,3,6- tetrahvdropyridine hydrochloride.
- Scheme II, Step C The toluene solution from example 3 containing the compound prepared in example 3 was diluted with isopropyl alcohol (1000 mL) and heated to 60°C. Then 2.5 M HCI/isopropanol (212 mL, 1.1 eq) was added over 30 minutes. The reaction mixture was then cooled in an ice bath and stirred for at least one hour at 0°C. The cooled mixture was then filtered, the solid rinsed with cold isopropyl alcohol and dried under vacuum at 50°C to provide the title compound (55-60%) as the HCl salt .
- step A A solution of 2.0M of n-BuLi in cyciohexane ( 11.99 mL, 24 mmol) was cooled to 5°C under a nitrogen atmosphere. TMEDA (3.71 mL, 24.6 mmol) was added dropwise keeping the exotherm under 10°C. Thiophenol (1.20 mL, 11.7 mmol) in 2 mL cyciohexane was added dropwise keeping the exotherm under 20°C. The resulting solution was allowed to stir to ambient temperature overnight. The thick white slurry was cooled to -50°C, and diluted with 2 mL of dry THF.
- step C A solution of methanesulfonic acid (0.98 mL, 15.11 mmol) in 5 mL toluene was cooled to 0°C. To this solution was added 1-N- carbethoxy-4-hydroxy-4-(2'-(2",2"-0-diethoxy)ethylthio-phenyl)piperidine (1.0 g, 2.52 mmol, prepared in example 5) in 5 mL of toluene dropwise at 0°C. The solution was then stirred at 10°C for 15 minutes, and slowly warmed to ambient temperature.
- R 6 and R 7 are each independently H or d-C ⁇ alkyl; m is the integer 0, 1 or 2; n is the integer 0, 1 or 2; and R 8 is H or a suitable nitrogen protecting group are preferred;
- R 1c are each independently H, F, Cl, Br, I, C C 6 alkyl, d-C ⁇ alkoxy, CF 3 , phenyl, or NO 2 , are preferred; with respect to substituent R 2 , compounds wherein R 2 is H, C 1 -C- 20 alkyl, OH, or
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14148199P | 1999-06-29 | 1999-06-29 | |
US141481P | 1999-06-29 | ||
PCT/US2000/011884 WO2001000620A2 (en) | 1999-06-29 | 2000-06-21 | Preparation of 7-substituted benzothiophenes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1196413A2 true EP1196413A2 (en) | 2002-04-17 |
Family
ID=22495874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00944592A Withdrawn EP1196413A2 (en) | 1999-06-29 | 2000-06-21 | Preparation of 7-substituted benzothiophenes |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1196413A2 (en) |
AU (1) | AU5866500A (en) |
WO (1) | WO2001000620A2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK148392D0 (en) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocyclic Compounds |
US6436964B1 (en) * | 1998-06-30 | 2002-08-20 | Eli Lilly And Company | Piperidine derivatives having effects on serotonin related systems |
-
2000
- 2000-06-21 EP EP00944592A patent/EP1196413A2/en not_active Withdrawn
- 2000-06-21 AU AU58665/00A patent/AU5866500A/en not_active Abandoned
- 2000-06-21 WO PCT/US2000/011884 patent/WO2001000620A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0100620A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001000620A3 (en) | 2001-07-19 |
WO2001000620A2 (en) | 2001-01-04 |
AU5866500A (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5661159A (en) | Quinolylbenzofuran derivatives as leukotriene antagonists | |
US6486153B1 (en) | Phenylindole derivatives as 5-HT2A receptor ligands | |
RU2345069C2 (en) | Method of obtaining 4-amino-3-quinolinecarbonitryls | |
WO2003013510A1 (en) | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | |
JP2011518173A5 (en) | ||
EP1412347A1 (en) | Process for the preparation of heterocyclic pentalene derivatives | |
WO2005113539A1 (en) | 3-arylsulfonyl-quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders | |
ZA200103249B (en) | 4-Aroyl-piperidin-CCR-3 receptor antagonists III. | |
KR20070058689A (en) | Methods for preparing indazole compounds | |
IL180737A (en) | Arylsulphonylstilbene derivatives, their pharmaceutical compositions and uses thereof for the manufacture of medicaments for treatment of conditions mediated by 5-ht 2a receptor activity | |
JP2001151771A (en) | Nitrogen-containing aromatic heterocyclic derivative | |
CN101993405A (en) | Indoline derivative as well as preparation method and application thereof | |
AU2003289903A1 (en) | Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
EP1487801A1 (en) | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepine derivatives with 5-ht6 receptor affinity for the treatment of cns disorders | |
JP2003500488A (en) | Sulfonamide compounds having pharmacological activity | |
JPH07110857B2 (en) | Piperazinyl- and piperidinyl-substituted cyclohexene and cyclohexane derivatives | |
US20040053956A1 (en) | Isoquinoline derivatives useful in the treatment of cns disorders | |
JP2006519798A (en) | Compound having activity on 5HT2c receptor and use thereof | |
WO2001000620A2 (en) | Preparation of 7-substituted benzothiophenes | |
JP4610740B2 (en) | Process for the preparation of 3- (substituted phenyl) -5-thienyl or furyl) -1,2,4-triazole and novel intermediates used therein | |
PL192837B1 (en) | Method of obtaining eprosartane | |
WO2005037827A1 (en) | Process for preparing benzimidazole thiophenes | |
US5817823A (en) | Method for synthesizing 2-substituted imidazoles | |
NO124687B (en) | ||
JPH0545587B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020129 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030423 |